Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Mills

Showing results (791-800 of 888) with videos related to

Pageof 89
Sort By:
Journal of Medicinal Chemistry|September 30, 2005
Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3Zhen Li, Weirong Chen, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic propertiesDooseop Kim, Liping Wang, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonistsLaura C Meurer, Paul E Finke, Sander G Mills, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2006
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivativesLaura C Meurer, Paul E Finke, Karen A Owens, et al.
British Journal of Cancer|July 10, 2020
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer modelYiannis Philippou, Hanna T Sjoberg, Emma Murphy, et al.
Bioorganic & Medicinal Chemistry Letters|September 14, 2010
Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activitiesHaifeng Tang, Yan Yan, Zhe Feng, et al.
Pageof 89

Showing results (791-800 of 888) with videos related to

Sort By:
Pageof 89
Journal of Medicinal Chemistry|September 30, 2005
Discovery of potent 3,5-diphenyl-1,2,4-oxadiazole sphingosine-1-phosphate-1 (S1P1) receptor agonists with exceptional selectivity against S1P2 and S1P3Zhen Li, Weirong Chen, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|October 10, 2001
1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activityJ J Hale, R J Budhu, E B Holson, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanesP E Finke, L C Meurer, B Oates, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2005
Potent 1,3,4-trisubstituted pyrrolidine CCR5 receptor antagonists: effects of fused heterocycles on antiviral activity and pharmacokinetic propertiesDooseop Kim, Liping Wang, Jeffrey J Hale, et al.
Bioorganic & Medicinal Chemistry Letters|January 25, 2005
Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonistsLaura C Meurer, Paul E Finke, Sander G Mills, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|November 27, 2001
Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infectionD Kim, L Wang, C G Caldwell, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2006
Cyclopentane-based human NK1 antagonists. Part 2: development of potent, orally active, water-soluble derivativesLaura C Meurer, Paul E Finke, Karen A Owens, et al.
British Journal of Cancer|July 10, 2020
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer modelYiannis Philippou, Hanna T Sjoberg, Emma Murphy, et al.
Bioorganic & Medicinal Chemistry Letters|September 14, 2010
Design and synthesis of a new class of malonyl-CoA decarboxylase inhibitors with anti-obesity and anti-diabetic activitiesHaifeng Tang, Yan Yan, Zhe Feng, et al.
Pageof 89